Beyond simple advertising, a new system is developing where patients can initiate treatment, get a digital prescription via telehealth, and use non-traditional channels to get medicine. This model thrives in areas where insurance creates friction and a cash price is viable.
Four key variables determine a drug's suitability for a direct-to-consumer (DTC) channel: it must be self-administered, the condition must be diagnosable via telehealth without in-person confirmation, it should have a lower price point, and be free of restrictive FDA regulations.
A surprising 25% of consumers paid entirely out-of-pocket for a healthcare service in the last year, most commonly for mental health. Critically, their stated maximum willingness to spend was nearly double their average annual spend, signaling significant unmet demand and price elasticity.
Contrary to the belief that startups will dominate, large, vertically integrated managed care companies are best suited to adapt to consumerism. Their existing scale across insurance, provider arms, technology, and pharmacy assets allows them to invest in and deliver the transparency and access consumers demand.